- Robust data demonstrates extremely high level of patient
satisfaction and increased spectacle independence for PanOptix® and
Vivity™ PCIOLs – underpinning the strength of these market-leading
technologies1-8
- ARGOS® Biometer with Image Guidance delivers substantial
time efficiencies for cataract surgery practices, surgeons and
patients9
- More than 60 abstracts highlighting the benefits of the
Alcon innovation
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people See Brilliantly, will present a breadth of data
during the American Society of Cataract and Refractive Surgery
(ASCRS) 2021 annual meeting, taking place July 23-27 in Las Vegas.
More than 60 abstracts featuring Alcon ophthalmic products and
equipment will be presented, reinforcing the Company’s
industry-leading portfolio. The full abstract book, registration
links for events taking place onsite and booth information is
available at MyAlconatASCRS.com.
“We are thrilled to be back in person at a large-scale meeting
with our ophthalmology community for the first time since 2019,”
said Sergio Duplan, President, North America at Alcon. “Alcon once
again has a significant presence at ASCRS, highlighting our ongoing
commitment to scientific and technological advancements as we
continue to pave the path forward in ophthalmic surgical
innovation.”
Of the abstracts to be presented, more than half will focus on
Alcon’s market-leading presbyopia-correcting intraocular lens
technologies, including AcrySof® Vivity™ IQ IOL, AcrySof® PanOptix®
IOL as well as the novel Clareon® IOL. The optical designs and
material of these IOLs provide patients a variety of options to See
Brilliantly, reinforcing Alcon’s commitment to innovation in this
space.
Reduced Spectacle Dependence and High Patient Satisfaction
with VivityTM IOL, the first and only non-diffractive extended
depth of focus (EDOF) IOL in the U.S.10
Key data continues to demonstrate that Vivity delivers an
extended range of vision while maintaining a monofocal-like visual
disturbance profile.1-4,10 Study findings are based on real-world,
patient-reported outcomes for those implanted with the Vivity
lens.1-4 The data affirms the results from a Vivity U.S. clinical
trial, which demonstrated:
- 94% and 92% of Vivity patients reported very good or good
vision at distance and arm’s length, respectively, without glasses
in bright light, with vision of 20/20 at distance, greater than
20/25 at intermediate and functional near (20/32).10,11*†
- 90% of patients implanted with Vivity™ were satisfied with
their results and would get the lens again.11*‡
Presentations will also showcase additional Vivity results and
key findings, including:
- The Revive Study: Long Term Outcomes of a Novel Non-Diffractive
Extended Vision IOL Versus Monofocal Control IOL, Presented by Dr.
Brian M. Shafer (July 25, 1:55-2:00 PM).
- Visual Outcomes and Quality of Vision after Implantation of a
New Presbyopia-Correcting Intraocular Lens with a Non-Diffractive
Design, Presented by, Dr. Cathleen McCabe (July 25, 9:10-9:15
AM).
- Visual Performance of Non-Diffractive Extended Depth of Focus
and Neutral Aspheric Monofocal Intraocular Lens, Presented by Dr.
Seth Pantanelli (July 25, 10:00-10:05 AM).
PanOptix® Trifocal IOL Provides Excellent Continuous
Vision.12,13 PanOptix is the first and only trifocal IOL in the
U.S. and is the most implanted trifocal IOL in the world.
With PanOptix, 20/20 near, intermediate, and distance vision is
now possible.13±° A meta-analysis of U.S. and worldwide data
reinforces that PanOptix IOL provides patients continuous 20/25 or
better vision from distance to near (33cm/13in);12 additional key
presentations include:
- A Prospective Randomized Comparison of Bilaterally Implanted
Extended Depth of Focus and Trifocal Intraocular Lenses, Presented
by Dr. Satish S. Modi (July 26, 10:05-10:10 AM).
- A Cost-Benefit Analysis Comparing Trifocal Intraocular Lens
(IOL) with Monofocal IOL from Patient Perspective in the USA,
Presented by Dr. John P. Berdahl (July 26, 10:55-11:00 AM).
- Evaluation of Quality of Vision and Spectacle Independence with
Bilateral Implantation of a New Trifocal Intraocular Lens,
Presented by Dr. Andrew C. Shatz (July 24, 8:00-8:05 AM).
ARGOS® Biometer Delivers Substantial Time Efficiencies to
Cataract Surgery Practices, Surgeons and Patients, as the
industry-leading Swept Source Optical Coherence Tomography (SS-OCT)
biometer equipped with image guidance for a faster and smarter
planning solution.14-18
At Alcon, we know that connectivity matters, and data being
presented at ASCRS highlights that ARGOS delivers substantial time
efficiencies for cataract surgery practices, surgeons, and patients
through its superior acquisition rate and integration
functionality.9 This time-efficiency model showed that for every
1,000 patients receiving a toric IOL, integrating ARGOS with image
guidance can save 58 hours and 51 minutes versus LENSTAR alone.9
Additional studies on ARGOS will be presented, including:
- Comparing the Toric Calculations with the Keratometric Readings
from a Swept-source OCT Biometer Versus a Scheimpflug Topographer,
Presented by Dr. H. John Shammas (July 25, 4:00-4:05 PM).
- Targeted Literature Review of the Current Burden and Outcomes
of Cataract Surgery with and without Image Guided Systems,
Presented by Dr. Sam Multack (July 23, 7:00-8:00 PM).
NGENUITY® 3D Visualization System Heads-Up Display Brings
Ergonomics to Surgical Experience; leading 3D visualization
system provides precision, depth and detail during cataract and
vitreoretinal surgery.19
In a new assessment of musculoskeletal (MSK) complaints, more
than 80% of ophthalmologists reported exacerbated MSK pain from the
postural position required when examining patients and performing
surgery with traditional binocular microscopes – up from 50-70%
reported in prior studies.20 A different study found that the
postural musculature was less activated with the NGENUITY 3D
Heads-up Display (HUD) than with Traditional Microscope (TOM) in
Ophthalmic Surgery. Alcon will present these studies along with
other key data at the meeting to further explore the benefits of
implementing the NGENUITY 3D HUD in Surgical practices:21
- Prospective Randomized Evaluation and Comparison of the Effect
of Decreased Illumination on Visual Recovery Following Cataract
Surgery, Presented by Dr. Eric D. Rosenberg (July 26, 10:47-10:52
AM).
Other studies of note will be presented at the meeting
including, but not limited to:
- Clinical and Refractive Outcomes after Topography-Guided
Refractive Surgery Planned Using Phorcides Analytic Surgery
Planning Software, Presented by Dr. Mark C. Lobanoff (July 25,
8:05-8:10 AM).
- In-Vitro Comparative Analysis of the Cavitation and Particle
Image Velocimetry Characteristics of Two Phacoemulsification Tips,
Presented by Dr. Jamie Zacharias (July 24, 8:40-8:45 AM).
- Comparison Between Systane iLux and Lipiflow in the Treatment
of Meibomian Gland Dysfunction (MGD): A 12-Month, Multicenter
Study, Presented by Dr. Joseph Tauber (July 24, 2:37-2:42 PM).
Alcon will be bringing connectivity to life during ASCRS with a
series of interactive activities. Watch this space as the Company
continues to innovate in digital health. Follow along on Alcon
social channels and join the conversation at #ConnectBrilliantly.
Visit the Alcon booth (#3601) during the meeting to learn more
about our surgical products and services, as well as our dry eye
devices portfolio, which helps doctors see and restore the ocular
surface health of their patients. For information on Alcon events,
activations and abstracts, please visit MyAlconatASCRS.com.
About ARGOS® Biometer with Image
Guidance
ARGOS is a non-invasive, non-contact biometer based on
sweptsource optical coherence tomography (SS-OCT). The device is
intended to acquire ocular measurements as well as perform
calculations to determine the appropriate intraocular lens (IOL)
power and type for implantation during intraocular lens placement.
Please refer to the ARGOS User Manual for a complete description of
proper use and maintenance, optical and technical specifications,
as well as a complete list of warnings and precautions.
About the AcrySof® IQ VivityTM
IOL
The non-diffractive AcrySof® IQ VivityTM Extended Vision
Posterior Chamber Intraocular Lens Model DFT015 (referred to as
AcrySof® IQ VivityTM IOL) is a UV-absorbing and blue light
filtering foldable intraocular lens (IOL). This IOL, compared to a
monofocal IOL, provides an extended range of vision from distance
to near without increasing the incidence of visual
disturbances.
Potential side effects: As with any surgery, there is an
implicit risk, whether or not the IOL is implanted. The
complications of the IOL implantation surgery ranges from minor
side effects (usually temporary) to serious complications. Patients
with previous illnesses or disorders (such as chronic infections of
the eye or eyelids, or diabetes) may present a higher risk of
complications. Temporary surgical complications include, but are
not limited to, reactions to medications such as irritation or mild
allergic response, bleeding, redness, itching of the eye,
sensitivity to light, swelling, corneal edema (swelling of the
cornea), problems with the iris, cell growth in the IOL, and an
increase temporary eye pressure. There is a small risk of needing
further surgical treatment (such as IOL replacement implanted by a
different one or surgery to improve vision) after the implantation
of the initial IOL.
About the AcrySof® IQ PanOptix®
Trifocal Intraocular Lens (IOL)
The AcrySof IQ PanOptix Trifocal IOL is a type of multifocal IOL
used to focus images clearly onto the back of your eye (retina) to
allow clear vision after the cataract removal. In addition, the
center of the AcrySof IQ PanOptix Trifocal IOL allows for better
near (reading) vision and intermediate (computer work) vision
versus what a monofocal lens would provide.
Potential Side Effects: Due to the design of multifocal IOLs,
there are some side effects that can be associated with the AcrySof
IQ PanOptix Trifocal IOL models. These may be worse than with a
monofocal IOL, including visual disturbances such as glare, rings
around lights, starbursts (rays around light sources), and reduced
contrast sensitivity (decrease in ability to distinguish objects
from their background, especially in dim lighting). These side
effects may make it more difficult to see while driving at night or
completing tasks in low lighting conditions such as at night or in
fog, or in a dimly lit room after surgery as compared to before
surgery.
Further, a toric IOL corrects astigmatism only when it is placed
in the correct position in the eye. There is a possibility that the
toric IOL could be placed incorrectly or could move within the eye.
If the toric lens is not positioned correctly following surgery,
the change in your astigmatism correction by the IOL, along with
any necessary correction with glasses, may cause visual
distortions. If the lens rotates in your eye, you may need
additional surgery to reposition or replace the IOL.
About the Clareon® Aspheric Hydrophobic
Acrylic IOL with the AutonoMe® Automated Pre-loaded Delivery
System
The Clareon® Aspheric Hydrophobic Acrylic Intraocular Lens (IOL)
is an artificial lens implanted in the eye of adult patients
following cataract surgery.
Potential side effects: As with any surgical procedure, there
are risks involved. These risks may include, but are not limited
to: infection; damage to the ocular structures – lining (inner
surface) of the cornea; damage to the iris (the colored diaphragm
around the pupil); the retinal layer that lines the inside back
wall of your eye may become separated from the tissue next to it
(retinal detachment); inflammation or swelling inside or outside
the eye; an increase in eye pressure that may not be controlled by
medicine; and you may need second surgical procedure. There is a
possibility that this IOL could be placed incorrectly or could move
within the eye. This may result in less improvement or a reduction
in vision, or it may cause visual symptoms.
About NGENUITY® 3D Visualization
System
The NGENUITY 3D Visualization System consists of a 3D
stereoscopic, high-definition digital video camera and workstation
to provide magnified stereoscopic images of objects during
micro-surgery. It acts as an adjunct to the surgical microscope
during surgery displaying real-time images or images from
recordings. Please refer to the User Manual for a complete list of
appropriate uses, warnings and precautions.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases, and refractive errors. Our more than 23,000 associates
are enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
References
- Allen, Quentin B., MD. Site Level Data from a Multicenter Study
of Patient Profiles, Satisfaction, and Visual Range of a Novel
Non-Diffractive Extended Vision IOL. ASCRS, Las Vegas, NV. 25 July
2021.
- Hovanesian, John A., MD. Evaluation of a Non-Diffractive
Multifocal IOL (Vivity) for Glare/Haloes, Spectacle Independence,
and Patient Satisfaction. ASCRS, Las Vegas, NV. 25 July 2021.
- Shafer, Brian M., MD. The Revive Study: Long Term Outcomes of a
Novel Non-Diffractive Extended Vision IOL Versus Monofocal Control
IOL. ASCRS, Las Vegas, NV. 25 July 2021.
- Shafer, Brian M., MD. One Year, Site-Level Outcomes of a Novel
Non-Diffractive Extended Vision Intraocular Lens Versus Control.
ASCRS, Las Vegas, NV. 25 July 2021.
- Blehm, Clayton G., MD. Evaluating Visual Acuity and Spectacle
Independence After Bilateral Implantation of a Trifocal Intraocular
Lens. ASCRS, Las Vegas, NV. 24 July 2021.
- Chang, John So-Min, MD. Early Clinical Outcome of a Trifocal
Intraocular Lens in Asian Eyes. ASCRS, Las Vegas, NV. 23 July
2021.
- Greenwood, Michael D., MD. Outcomes and Patient Satisfaction of
a Trifocal IOL in Post-Refractive Patients. ASCRS, Las Vegas, NV.
24 July 2021.
- Mueller, Brett H. II, DO, PhD. Prospective Analysis to Assess
Placing a Panoptix Trifocal LENS in Patients Who Have HAD Myopic
Laser Vision Correction Surgery. ASCRS, Las Vegas, NV. 26 July
2021.
- Woodard, Lawrence, MD. Time Efficiency of an Innovative Optical
Biometer in Cataract Surgery: A Time-and-Motion Study. ASCRS. Las
Vegas, NV. 23 July 2021.
- AcrySof® IQ Vivity™ Extended Vision IOL DFU. Alcon
Laboratories, Inc.; 2020.
- Alcon Data on File. 2019.
- Maxwell, Andrew W., MD, PhD. Post-operative Visual Outcomes
with a Diffractive Trifocal Intraocular Lens: A Meta-analysis of
USA and Worldwide patients. ASCRS, Las Vegas, NV. 26 July
2021.
- AcrySof® IQ PanOptix DFU. Alcon Laboratories, Inc.; 2019
- Tamaoki A, Kojima T, Hasegawa A, et al. Clinical Evaluation of
a New Swept-source Optical Coherence Biometer That Uses Individual
Refractive Indices to Measure Axial Length Cataract Patients.
Ophthalmic Res. 2019;19;1-13.
- Shammas HJ, Ortiz S, Shammas MC, Kim SH, Chong C. Biometry
Measurements Using a New Large Coherence-Length Swept-Source
Optical Coherence Tomographer. J Cataract Refract Surg. 2016;
42:50-61.
- Hussaindeen JR, Mariam EG, Arunachalam S, et al. Comparison of
Axial Length Using a New Swept-Source Optical Coherence
Tomography-Based Biometer. PLOS One. December 2018.
- Zeiss IOL Master 700 510k Submission 2015.
- Whang, Woong-Joo. Predictive Accuracy of Partial Coherence
Interferometry and Swept-source Optical Coherence Tomography For
Intraocular Lens Power Calculation. Scientific Report. September
2018.
- Alcon Data on File. 2016.
- Tan, Nicholas E., Assessment of Musculoskeletal Complaints
among Ophthalmologists. ASCRS, Las Vegas, NC. 26 July 2021.
- Hura, Arjan, MD. Intraoperative Electromyogram Analysis of
Postural Musculature with 3D Heads-up Display vs. Traditional
Microscope in Ophthalmic Surgery. ASCRS, Las Vegas, NV. 26 July
2021.
*Results from a prospective, randomized, parallel group,
subject- and assessor-masked, multisite trial of 107 subjects
bilaterally implanted with the AcrySof® IQ Vivity™ IOL and 113 with
the AcrySof® IQ IOL with 6 months’ follow-up. Patient-reported
outcomes for spectacle independence were evaluated subjectively
through IOLSAT questionnaire.
‡In response to the question asked 6 months after surgery:
“Given your vision today, if you had to do it all over, would you
have the same lens implanted again?”
†Patients were asked, “How well did you see without wearing
eyeglasses in the past 7 days?” Patients who reported not using
glasses at least some of the time were asked to rate their quality
of vision.
±Based on mean value of binocular defocus curve at near,
intermediate, and distance at 6 months (n=127).
°Snellen VA was converted from logMAR VA. A Snellen notation of
20/20-2 or better indicates a logMAR VA of 0.04 or better, which
means 3 or more of the 5 ETDRS chart letters in the line were
identified correctly.
Disclaimer
This press release contains
“forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: “anticipate,” “intend,” “commitment,” “look
forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,”
“should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210722005996/en/
Investor Relations Christina
Cheng + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com Media
Relations Melanie McCoy + 1 817 363 1247 (Fort Worth) +
1 682 304 8657 (Fort Worth) Melanie.McCoy@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024